These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 8932846)

  • 1. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC
    Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J; Ringdén O
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT).
    Frassoni F; Labopin M; Gluckman E; Prentice HG; Vernant JP; Zwaan F; Granena A; Gahrton G; De Witte T; Gratwohl A; Reiffers J; Gorin NC
    Bone Marrow Transplant; 1996 Jan; 17(1):13-8. PubMed ID: 8673048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
    Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
    Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
    Carlens S; Ringdén O; Aschan J; Hägglund H; Ljungman P; Mattsson J; Remberger M
    Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation.
    Hiraoka A; Ohashi Y; Okamoto S; Moriyama Y; Nagao T; Kodera Y; Kanamaru A; Dohy H; Masaoka T;
    Bone Marrow Transplant; 2001 Jul; 28(2):181-5. PubMed ID: 11509936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.
    Chao NJ; Schmidt GM; Niland JC; Amylon MD; Dagis AC; Long GD; Nademanee AP; Negrin RS; O'Donnell MR; Parker PM
    N Engl J Med; 1993 Oct; 329(17):1225-30. PubMed ID: 8413388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia.
    Nordlander A; Mattsson J; Ringdén O; Leblanc K; Gustafsson B; Ljungman P; Svenberg P; Svennilson J; Remberger M
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):195-203. PubMed ID: 14993885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants.
    Olsson R; Remberger M; Hassan Z; Omazic B; Mattsson J; Ringdén O
    Eur J Haematol; 2010 Apr; 84(4):323-31. PubMed ID: 20002156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
    J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
    Schwinghammer TL; Bloom EJ
    Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis.
    Carlens S; Ringdén O; Remberger M; Lönnqvist B; Hägglund H; Klaesson S; Mattsson J; Svahn BM; Winiarski J; Ljungman P; Aschan J
    Bone Marrow Transplant; 1998 Oct; 22(8):755-61. PubMed ID: 9827972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings.
    Ringdén O; Klaesson S; Sundberg B; Ljungman P; Lönnqvist B; Persson U
    Bone Marrow Transplant; 1992 Jan; 9(1):19-25. PubMed ID: 1543946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
    Atkinson K; Downs K
    Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.
    Barrett AJ; Mavroudis D; Tisdale J; Molldrem J; Clave E; Dunbar C; Cottler-Fox M; Phang S; Carter C; Okunnieff P; Young NS; Read EJ
    Bone Marrow Transplant; 1998 Mar; 21(6):543-51. PubMed ID: 9543057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants.
    Hoyt R; Ritchie DS; Roberts AW; Macgregor L; Curtis DJ; Szer J; Grigg AP
    Bone Marrow Transplant; 2008 Apr; 41(7):651-8. PubMed ID: 18176619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.